Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study

Main Article Content

E Guttman-Yassky
A Blauvelt
L.F. Eichenfield
A Paller
A Armstrong
J Drew
R Gopalan
E Simpson

Keywords

atopic dermatitis, lebrikizumab

Abstract

Abstract not available.

References

1. Bieber T. Ann Dermatol. 2010;22(2):125-37.

2. Drucker AM, Wang AR, Li WQ, et al. J Invest Dermatol. 2017;137(1):26-30.

3. Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Exp Dermatol. 2019;28(7):756-68.

4. Bieber T. Allergy. 2019. [Epub ahead of print]

5. Tsoi LC, Rodriguez E, Degenhardt F, et al. J Invest Dermatol. 2019; 139(7):1480-89.

6. Simpson EL, Flohr C, Eichenfield LF, et al. J Am Acad Dermatol. 2018;78(5):863-71.